CIPN represents a significant opportunity for Bexion.

In 2020, there were an estimated 3 Million cases of CIPN in the United States with global annual cases surpassing 13 Million.2 With cancer diagnosis and survival rates on the rise, CIPN rates are also expected to increase warranting a heightened urgency to address this serious unmet clinical need.

Market opportunity map

“Considering the significant and growing unmet need plus the lack of effective treatments, the market potential for an FDA approved CIPN treatment would likely be in the blockbuster category, exceeding $1 billion in annual sales.”

Jim Beach, Operations, Bexion Pharmaceuticals
References
  1. The Foundation of Peripheral Neuropathy. https://www.foundationforpn.org/what-is-peripheral-neuropathy/types-risk-factors/. Accessed January 22, 2021
Neuroprotective Outcomes
Market Opportunity
What is CIPN?
Impact of CIPN